Drugs / Favezelimab/Pembrolizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02720068 | May 2016 → Mar 2024 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Favezelimab/Pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02720068 ↗ |
| Route | Intravenous | “IV infusion” NCT02720068 ↗ |